Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edmond M Kwan

Showing results (1-10 of 53) with videos related to

Pageof 6
Sort By:
Current Opinion in Urology|May 27, 2020
Chemotherapy, not androgen receptor-targeted therapy should be used upfront for metastatic hormone-sensitive prostate cancer. PRO: docetaxel chemotherapy should be the default consideration in metastatic hormone-sensitive prostate cancerEdmond M Kwan, Arun A Azad
The Prostate|June 3, 2022
Androgen receptor genomic alterations and treatment resistance in metastatic prostate cancerEdmond M Kwan, Alexander W Wyatt
European Urology|January 11, 2025
…But Words Will Never Hurt MeIan D Davis, Angelyn Anton, Edmond M Kwan
Cellular Oncology (Dordrecht, Netherlands)|October 28, 2018
Cell-free DNA in cancer: current insightsHeidi Fettke, Edmond M Kwan, Arun A Azad
Critical Reviews in Oncogenesis|August 22, 2022
Genomic Alterations to Guide Treatment Selection in Metastatic Prostate CancerAmy Davies, Arun A Azad, Edmond M Kwan
Frontiers in Oncology|November 28, 2022
Towards clinical implementation of circulating tumor DNA in metastatic prostate cancer: Opportunities for integration and pitfalls to interpretationEdmond M Kwan, Alexander W Wyatt, Kim N Chi
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 13, 2025
Safety and Efficacy of 20 Cycles of [<sup>177</sup>Lu]Lu-PSMA-617 for Metastatic Castration-Resistant Prostate CancerKerry E Jewell, James P Buteau, Elizabeth Medhurst, et al.
BJU International|October 30, 2019
Novel agents for metastatic hormone-sensitive prostate cancer - a practice guide for urologistsIsaac A Thangasamy, Edmond M Kwan, Jiasian Teh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 25, 2025
p-AKT protein expression predicts response to AKT inhibitor combined with docetaxel therapy in adenocarcinoma and neuroendocrine prostate cancerHipacia Werneck Gomes, Natalie L Lister, Shivakumar Keerthikumar, et al.
Asia-Pacific Journal of Clinical Oncology|February 1, 2019
Timing of brain metastases development in metastatic renal cell cancer patients treated with targeted therapies and survival outcomes: An Australian multicenter studyFrancis J Ha, Lavinia Spain, Anthony Dowling, et al.
Pageof 6

Showing results (1-10 of 53) with videos related to

Sort By:
Pageof 6
Current Opinion in Urology|May 27, 2020
Chemotherapy, not androgen receptor-targeted therapy should be used upfront for metastatic hormone-sensitive prostate cancer. PRO: docetaxel chemotherapy should be the default consideration in metastatic hormone-sensitive prostate cancerEdmond M Kwan, Arun A Azad
The Prostate|June 3, 2022
Androgen receptor genomic alterations and treatment resistance in metastatic prostate cancerEdmond M Kwan, Alexander W Wyatt
European Urology|January 11, 2025
…But Words Will Never Hurt MeIan D Davis, Angelyn Anton, Edmond M Kwan
Cellular Oncology (Dordrecht, Netherlands)|October 28, 2018
Cell-free DNA in cancer: current insightsHeidi Fettke, Edmond M Kwan, Arun A Azad
Critical Reviews in Oncogenesis|August 22, 2022
Genomic Alterations to Guide Treatment Selection in Metastatic Prostate CancerAmy Davies, Arun A Azad, Edmond M Kwan
Frontiers in Oncology|November 28, 2022
Towards clinical implementation of circulating tumor DNA in metastatic prostate cancer: Opportunities for integration and pitfalls to interpretationEdmond M Kwan, Alexander W Wyatt, Kim N Chi
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 13, 2025
Safety and Efficacy of 20 Cycles of [<sup>177</sup>Lu]Lu-PSMA-617 for Metastatic Castration-Resistant Prostate CancerKerry E Jewell, James P Buteau, Elizabeth Medhurst, et al.
BJU International|October 30, 2019
Novel agents for metastatic hormone-sensitive prostate cancer - a practice guide for urologistsIsaac A Thangasamy, Edmond M Kwan, Jiasian Teh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 25, 2025
p-AKT protein expression predicts response to AKT inhibitor combined with docetaxel therapy in adenocarcinoma and neuroendocrine prostate cancerHipacia Werneck Gomes, Natalie L Lister, Shivakumar Keerthikumar, et al.
Asia-Pacific Journal of Clinical Oncology|February 1, 2019
Timing of brain metastases development in metastatic renal cell cancer patients treated with targeted therapies and survival outcomes: An Australian multicenter studyFrancis J Ha, Lavinia Spain, Anthony Dowling, et al.
Pageof 6